The power and pitfalls of omics part 2: epigenomics, transcriptomics and ME/CFS
Simon McGrath concludes his blog about the remarkable Prof George Davey Smith's smart ideas for understanding diseases, which may soon be applied to ME/CFS.
Discuss the article on the Forums.

IiME have just received this letter from NICE

Discussion in 'General ME/CFS News' started by Countrygirl, Dec 6, 2016.

  1. Countrygirl

    Countrygirl Senior Member

    Messages:
    2,994
    Likes:
    15,417
    UK
    Dear Stakeholder

    I am writing to advise you that NICE has commenced its formal check of the need to update the clinical guideline CG53 Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management.

    In 2014 this guideline was added to the clinical guidelines static list as no quality standard had been commissioned for this topic and no major ongoing studies completing within the next 3-5 years were identified. Guidelines on the static list remain in existence and will be considered for new evidence at 5-year intervals. In the case of CG53 the static list review was due in 2019. However, if important new evidence is notified we can remove the guideline from the static list and carry out a full guideline surveillance review.
    In 2015 we were advised of 3 US reports that indicated there are likely to be changes in the diagnostic criteria in this field that will have implications for the guideline in the future, but not until after the proposed 2 year validation of the diagnostic criteria is completed. In view of these reports we have decided to commence a formal check of the need to update the guideline earlier than the 5 year interval. We have since been made aware of new information about the 2011 PACE trial, and we will also consider that in the review.

    The guideline surveillance review has been scheduled for review at the beginning of 2017 and a decision is expected to be published by summer 2017. A surveillance report will be developed to communicate the update decision and provide a commentary on approximately 3 articles felt to be of particular interest within this topic. The exact publication date will depend on the progress of the review and the proposed update decision. We will email stakeholders when the report has been published.
    There will be a 2-week consultation with registered stakeholders if information summarised indicates that a 'no update' decision should be considered. There is no consultation if the decision is to update the guideline because it has been based on the availability of new evidence, and is usually supported by stakeholders. It is important to note that if the decision is to update the guideline then the update will be developed in accordance with NICE processes for updating guidelines. The timescales for any update of the guideline will depend on the size and extent of the required update and available capacity.

    Consultation dates and times are posted in advance on the guideline page on the NICE website, and stakeholders are reminded by email.


    www.nice.org.uk
     
  2. Countrygirl

    Countrygirl Senior Member

    Messages:
    2,994
    Likes:
    15,417
    UK
    So who are the stakeholders? I think Prof EC was involved in the preparation of the NICE guidelines and she is unlikely to approve of a revision that reflects a physical aetiology. Downgrading PACE would also impact her MAGENTA and FITNET trials.

    It would be helpful to know who else is involved.
     
  3. Simon

    Simon

    Messages:
    1,919
    Likes:
    14,452
    Monmouth, UK
    Thanks for the post. 2 years from 2015 US IOM report (for validation) would take us to 2017.

    Interesting - is that the recovey and improvers data from Alem Matthees's FOI request (and subsequent analysis)?
     
  4. AndyPR

    AndyPR Senior Member

    I can't answer who are stakeholders but who can register as stakeholders are
    from https://www.nice.org.uk/get-involved/stakeholder-registration, which I got to from https://www.nice.org.uk/guidance/cg53
     
  5. Esther12

    Esther12 Senior Member

    Messages:
    8,449
    Likes:
    28,522
    Gone to www.s4me.info
    Someone had just posted NICE's list of stakeholders... it looked like a couple of hundred organisations!
     
  6. JoanDublin

    JoanDublin Senior Member

    Messages:
    369
    Likes:
    1,926
    Dublin, Ireland
  7. Esther12

    Esther12 Senior Member

    Messages:
    8,449
    Likes:
    28,522
    Gone to www.s4me.info
    I wonder if Phoenix Rising should apply @Mark ?

    MEAction UK? Anyone/everyone else?
     
  8. ryan31337

    ryan31337 Senior Member

    Messages:
    444
    Likes:
    986
    South East, England
    Quick, get an ineffectual update in before Fluge & Mella publish the game changing stuff. Sorry can't revise again until 202x... :rolleyes:
     
  9. AndyPR

    AndyPR Senior Member

  10. worldbackwards

    worldbackwards A unique snowflake

    Messages:
    2,091
    Likes:
    10,358
    Earth
    Perhaps the British Association of Amateur Dramatics will get involved as well.
     
  11. slysaint

    slysaint Moved to https://www.s4me.info/index.php

    Messages:
    2,124
    Likes:
    11,462
  12. Binkie4

    Binkie4 Senior Member

    Messages:
    517
    Likes:
    2,402
  13. Binkie4

    Binkie4 Senior Member

    Messages:
    517
    Likes:
    2,402
  14. Esther12

    Esther12 Senior Member

    Messages:
    8,449
    Likes:
    28,522
    Gone to www.s4me.info
    Valentijn and slysaint like this.
  15. slysaint

    slysaint Moved to https://www.s4me.info/index.php

    Messages:
    2,124
    Likes:
    11,462
    Anyone know how these groups are set up if and when the guidelines are reviewed? @charles shepherd
     
    Binkie4 likes this.
  16. Ysabelle-S

    Ysabelle-S Highly Vexatious

    Messages:
    523
    Likes:
    4,041
    Yes, this is how I feel about it too. It concerns me that they could be concluding this a bit too soon, before we have more information. Will the phase III Rituximab trial results be known at all by closing? What about other developments? It could be that this leads in the longer term to more delay if they close on this too soon. It's felt recently that the British medical establishment, at least those who have been involved in or supportive of those hijacking this illness, have been circling the wagons.
     
    Invisible Woman, Jo Best and Barry53 like this.
  17. Sidereal

    Sidereal Senior Member

    Messages:
    3,095
    Likes:
    17,172
    Well that's terrible news. This review is coming too soon to include any of the gamechanging information which will appear in the peer reviewed literature at a later date such as the Matthees et al reanalysis of PACE, the Phase III rituximab trial and the cyclophosphamide trial.
     
  18. Binkie4

    Binkie4 Senior Member

    Messages:
    517
    Likes:
    2,402
    Is this an actual review or a decision whether to review? If it is the latter, how long will it take to do a review which could affect the guideline?
     
    slysaint and Valentijn like this.
  19. BruceInOz

    BruceInOz Senior Member

    Messages:
    172
    Likes:
    1,003
    Tasmania
    Do we know what these three reports are? Do they actually list them somewhere or are we left to speculate?
     
  20. Sasha

    Sasha Fine, thank you

    Messages:
    12,778
    Likes:
    34,181
    UK
    I don't think that's the case:

    I think they can do a review at any time if important new evidence comes in.
     

See more popular forum discussions.

Share This Page